Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The tendency within the weekly time frame is positive above the technical support level at 12.32 EUR
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at EUR 17.74.
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
ABLYNX50.12%1 176
INCYTE CORPORATION13.96%24 254
QUINTILES IMS HOLDINGS INC33.89%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.15%19 730
ALNYLAM PHARMACEUTICALS, IN..208.84%10 783
SEATTLE GENETICS, INC.21.30%9 108
IONIS PHARMACEUTICALS INC33.58%7 945
QIAGEN NV17.88%7 941
ALKERMES PLC-8.08%7 850
ICON PLC52.07%6 187
INC RESEARCH HOLDINGS INC5.61%5 663
EXACT SCIENCES CORPORATION248.95%5 552
CHARLES RIVER LABORATORIES ..50.54%5 459
UNITED THERAPEUTICS CORPORA..-16.25%5 218
PRA HEALTH SCIENCES INC49.49%5 162
More Results
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 16,7x
EV / Sales 2018 18,0x
Capitalization 990 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABLYNX
Duration : Period : Day
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Duration : Period : Week
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders